Follow RSS for latest reports on this topicRelvar Ellipta - Market Research and Reports

Relvar Ellipta (FF/VI) is the first once-daily, inhaled corticosteroid/long-acting beta agonist (ICS/LABA) combination for the regular treatment of asthma in adults and adolescents aged 12 years and older approved in Japan. Relvar Ellipta contains the ICS fluticasone furoate (FF) and the LABA vilanterol (VI) and may be prescribed in two doses – 100/25 mcg and 200/25 mcg. Both dosages are administered using the Ellipta, a new dry powder inhaler (DPI).

For further information open http://www.gsk.com/

BioPortfolio's Easy Ordering System

  1. Search for the report you need from our store
  2. Make online payment with our easy checkout process
  3. Receive PDF report via email

Easy Online Payment or Pro Forma Invoice

We accept the following credit cards...



or can supply a pro-forma invoice if required.

Related Reports:

We found 9 reports that matched your search.

Refine your search, and find more matches, using the form above.

Additional Searches

You may also like to search separately for: Relvar Ellipta

We Stock...

{STICKYFOOTERMOBILE}